Human Anti-HIV-1 gp120 Recombinant Antibody (clone VRC03)

CAT#: PABL-155

Recombinant Human neutralizing Antibody (VRC03) is capable of binding to HIV-1 env, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-HIV-1 env mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-HIV-1 env mAb and CL of human light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition.

Published Data
Figure 1 Analysis of neutralization by MAbs VRC03, VRC06, and VRC06b against a panel of 178 Env pseudoviruses consisting of representatives from the major circulating clades of HIV-1. Dendrograms made by the neighbor-joining method show the protein distances of the Env gp160 sequences derived from 178 HIV-1 isolates. The clade B reference strain HXBc2 was used to root the tree, and the amino acid distance scale is indicated with a value of 1% distance. The clades of HIV-1 group M, including circulating recombinant forms (CRFs), are indicated. Neutralization potency of VRC03, VRC06, and VRC06b is indicated by the color of the branch for each virus. The data under the dendrograms show the percentages of viruses neutralized with an IC50 of <50 μg/ml and <1 μg/ml, and the geometric mean titer (GMT) of IC50 for viruses neutralized with an IC50 of <50 μg/ml. Figure 2 Binding of VRC03, VRC06, and VRC06b to JR-FL gp160ΔCT-transfected 293T cell surface by FACS assay, represented by MFI (mean of fluorescence intensity). JR-FL gp160ΔCT is the cleaved trimer; JR-FL gp160ΔCT cleavage-defective is the uncleaved trimer, which contains two mutations that render it cleavage defective. Figure 3 VRC06 neutralization potency against JR-FL gp160ΔCT virus was affected by Env mutations leading to an alteration of neutralization sensitivity. Top graphs, Env mutants Δ301 and T569A/I675V display enhanced neutralization sensitivity to CD4bs MAb F105 but substantially decreased neutralization sensitivity to VRC06; the bar graphs on the bottom depict the effects of the Env mutations Δ301 and T569A/I675V on the HIV sensitivity (IC50 values) to VRC06 and other CD4bs ligands. Figure 4 VRC06 and VRC06b displayed unique binding properties for Env gp120. (A) VRC06 and VRC06b preferred recognition of Env of CD4-bound conformation (stabilized core, 2CC) and of trimeric context YU2 gp140-F trimer. The CoRbs MAb 17b was used as control. Figure 5 Coexpressed CD4 competes for ligands that recognize the Env CD4-binding site.

Specifications

  • Host Species
  • Human
  • Type
  • Human IgG
  • Species Reactivity
  • HIV-1
  • Clone
  • VRC03
  • Applications
  • WB, ELISA, Neut, FuncS

Product Property

  • Purity
  • >95% as determined by SDS-PAGE
  • Concentration
  • Please refer to the vial label for the specific concentration.
  • Buffer
  • PBS
  • Preservative
  • No preservatives
  • Storage
  • Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The antibody was validated for FC, Neut and ELISA. For details, refer to published data.

Target

  • Alternative Names
  • ENV; gp160; envelope glycoprotein; Envelope surface glycoprotein gp160; precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for PABL-155. Click the button above to contact us or submit your feedback about this product.

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "Clone VRC03"

See other products for "HIV-1 gp120"

Select a product category from the dropdown menu below to view related products.

CAT Product Name Application Type
PABC-066 Human Anti-HIV-1 gp120 coat protein Recombinant Antibody (clone Yvo) ELISA, Neut Human IgM
CAT Product Name Application Type
MRO-135LC Anti-HIV-1 gp120 Recombinant Antibody (CAG1-51-4) ELISA, WB, Neut Chimeric antibody (mouse/human)
MRO-135LC-S(P) Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
MRO-135LC-F(E) Anti-HIV-1 gp120 Recombinant Antibody Fab Fragment (CAG1-51-4) ELISA, WB Chimeric antibody (mouse/human)
CAT Product Name Application Type
MOR-4220 Rabbit Anti-HIV-1 gp120 Recombinant Antibody (clone SI299DS) WB, ELISA Rabbit IgG
CAT Product Name Application Type
PABX-101-S(P) Human Anti-HIV-1 gp120 Recombinant Antibody scFv Fragment (PABX-101-S(P)) WB, ELISA, FuncS Human scFv
Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare